Non-invasive Prenatal test Claria NIPT is a
simple, safe, and non-invasive prenatal screening test that provides assurance
to expectant parents with accurate genetic information about their baby. Claria
NIPT Test uses advanced bioinformatics technology to evaluate fetal DNA (of
placental origin) in maternal blood to identify genetic variations leading to
disorders.
Trisomy 21 (Down Syndrome)
Trisomy 18 (Edwards’ Syndrome)
Trisomy 13 (Patau syndrome)
Turner Syndrome (Monosomy X/XO)
Klinefelter Syndrome (XXY)
Triple X (XXX)
Jacob’s Syndrome (XYY)
Rare Autosomal Aneuploidies (RAA) include
trisomies in chromosomes other than 21, 18 and 13 and monosomies in all 22
chromosomes.
Claria NIPT Advanced screens for RAAs in
addition to Trisomy 13, 18, 21 and sex chromosomes.
Key Highlights of Claria NIPT
Comprehensive view of the fetal genome
Screens entire fetal genome and not just
trisomies in chromosomes 21, 18, and 13
Enhanced Test Performance
Sensitivity and specificity of >99.9%
for Trisomy 21, 18, 13
>99% call rate
Low Test Failure Rates
Claria NIPT offers >99% call rate.
Fastest Test results
The Claria NIPT offers a fast three-step
automated workflow for NIPT
The turnaround time is less than or equal
to 10working days
Specimen
8-10ml of maternal blood to be collected in
special kit provided by Nita Labs.
Follow sample collection process as
mentioned in KIT.
After sample collection rotate the streck
tube 10 times clockwise and 10 times anti clockwise.
Methodology:
Circulating cell-free DNA (cfDNA), from
both the fetus and the mother, is found in maternal blood. On average, ~10% of
the cfDNA circulating in maternal blood is from the fetus. Highly sensitive
Next Generation Sequencing (NGS), which uses millions of sequences reads per
sample, can detect and measure aneuploidy within this mixed sample.
Quantitative differences in cfDNA in maternal blood can be used to distinguish
fetuses affected with trisomy 21 (and other foetal aneuploidies) from those
that are unaffected.
Claria NIPT based on Illumina VeriseqTM
Solution v2 brings this whole-genome sequencing (WGS) approach to NIPT.
Sequencing of the full fetal genome provides a comprehensive view of the
chromosomes. This method offers an enhanced counting technique along with
cutting edge algorithms to determine the risk of aneuploidies based on a ratio
between chromosomes of interest to multiple reference chromosome.
Why do you need the NIPT test?
Helps identify fetuses at risk of serious
chromosomal abnormality
Gives reassurance to expecting parents
Leads to better management of a child’s
genetic health by providing early information.
Prepares for the birth and early
intervention wherever possible
When can the NIPT test be done?
The NIPT screening test can be performed
from as early as 10 weeks of pregnancy.
Who needs to get tested?
All pregnant women who need insight into
their baby’s development can avail the test, regardless of their age. Claria
NIPT is recommended for all types of pregnancies. Medical societies today
support the use of NIPT as the first line of screening for all pregnancies,
irrespective of the risk.
For physicians, it is important to
recommend this test for pregnancies where:
The woman is above 30 years of age.
A high risk for abnormality is found serum
screening.
Certain abnormalities on ultrasound are
identified.
There is a family history of chromosomal
conditions or birth defects.
Couples have had a child with a chromosomal
disorder.
A couple has a history of infertility or
pregnancy loss (miscarriages or stillbirths).
How is Claria NIPT better than others?
High sensitivity/specificity for low false
positive and negative rates.
It has an accuracy of over 99.9%.
Only NIPT to process all samples at our
CAP* accredited MedGenome lab in India, enabling accurate and faster reporting.
